Recce Pharmaceuticals Announces Third-Quarter 2020 Financial Results and Provides Operational Highlights
Highlights: Strong cash balance of A$25.68 million after successful capital raising Phase I human clinical trial to evaluate RECCE® 327 (I.V.) in healthy subjects at leading clinical research organization, Adelaide’s CMAX SARS-CoV-2 domestic and …